Interpretation of changes in circulating tumor cell counts.

The presence of circulating tumor cells (CTCs) in the blood of cancer patients may guide the use of therapy. We investigated how to evaluate a reduction in the number of CTCs after administration of therapy. CTCs were enumerated with the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients before start of a new line of chemotherapy and after initiation of therapy. Different means to express changes in CTC counts were evaluated with respect to overall survival (OS). A static CTC cutoff is the best method to determine whether a therapy is effective. This is exemplified by the highest Cox hazard ratio of 2.1 for OS; three methods to express relative differences performed worse. A lookup table is provided from which the significance of a change in CTCs can be derived. The aim of therapy should be the elimination of all CTCs. A period of 10 to 12 weeks of therapy is needed to reach the treatment effect on CTCs.

• Publication year

  2012

• Venue

  Translational Oncology

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1593/TLO.12247PMID 23323160PMCID PMC3542841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

  2012cited by this paper
• Challenges in the Enumeration and Phenotyping of CTC

  2012cited by this paper
• Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

  2012cited by this paper
• Circulating melanoma cells and survival in metastatic melanoma.

  2011cited by this paper
• Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

  2011cited by this paper
• Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer

  2010cited by this paper
• Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

  2010cited by this paper
• Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

  2009cited by this paper
• Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

  2009cited by this paper
• Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.

  2009cited by this paper
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  2008cited by this paper
• Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

  2008cited by this paper
• Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan

  2008cited by this paper
• Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

  2007cited by this paper
• Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

  2007cited by this paper
• Statistical considerations for enumeration of circulating tumor cells

  2007cited by this paper
• Circulating tumor cells (CTC) in newly diagnosed breast or colorectal cancers

  2007cited by this paper
• Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

  2006cited by this paper
• Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

  2006cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004influential reference
• Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases

  2004cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper

• Liquid biopsy in cancer diagnosis and prognosis: a paradigm shift in precision oncology

  2026cites this paper
• Blood tumor load: combining biomarkers to increase the proportion of informative patients

  2025cites this paper
• Tailoring treatment for advanced and/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysis.

  2025cites this paper
• Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors

  2025cites this paper
• Clinical Significance of Circulating Tumor Cells in Patients with Esophageal Cancer

  2022cites this paper
• Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes

  2022cites this paper
• Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

  2021cites this paper
• Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer

  2020cites this paper
• Nanoscale metal-organic frameworks in detecting cancer biomarkers.

  2020cites this paper
• Deep learning of circulating tumour cells

  2020cites this paper
• Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer

  2020cites this paper
• Future perspectives from lung cancer pre-clinical models: new treatments are coming?

  2020cites this paper
• Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy.

  2019cites this paper
• Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

  2019cites this paper
• Short-Term Circulating Tumor Cell Dynamics in Mouse Xenograft Models and Implications for Liquid Biopsy

  2019cites this paper
• Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients

  2018cites this paper
• CTC Technologies and Tools

  2018cites this paper
• Health economic impact of liquid biopsies in cancer management

  2018cites this paper
• How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring

  2018cites this paper
• Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.

  2017cites this paper
• Circulating tumor cells: quintessential precision oncology presenting challenges for biology

  2017cites this paper
• Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

  2016cites this paper
• Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer

  2016cites this paper
• Improving the CellSearch® system

  2016cites this paper
• Challenges in circulating tumor cell detection by the CellSearch system

  2016cites this paper
• A novel approach for next‐generation sequencing of circulating tumor cells

  2016cites this paper
• Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy

  2015cites this paper
• A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

  2015cites this paper
• Circulating tumor cells before and during follow-up after breast cancer surgery.

  2015cites this paper
• Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

  2015influential citation
• Self-seeding microwell chip for the isolation and characterization of single cells.

  2015cites this paper
• Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells.

  2015cites this paper
• A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

  2014cites this paper
• The promise of circulating tumor cell analysis in cancer management

  2014cites this paper
• Minimal residual disease testing in hematologic malignancies and solid cancer

  2014cites this paper
• New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer

  2014cites this paper
• Recent developments in prognostic and predictive testing in uveal melanoma

  2014cites this paper
• Circulating cancer cells are potential weapon for future generations.

  2014cites this paper
• Detection of Circulating Tumor Cells

  2014cites this paper
• Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis

  2013cites this paper
• Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy

  2013cites this paper
• Metastasis and Circulating Tumor Cells

  2012cites this paper